In vivo electroporation of plasmid DNA (DNA-EP) is an efficient and safe method for vaccines resulting in increased DNA uptake, enhanced protein expression and increased immune responses to the target antigen in a variety of species. To further enhance the efficacy of DNA-EP, we have evaluated the toll-like receptor7 (TLR7) agonist-2, 9, substituted 8-hydroxyadenosine derivative or SM360320-as an adjuvant to vaccines against HER2/neu and CEA in BALB-neuT and CEA transgenic mice (CEA.Tg), respectively. SM360320 induced in vivo secretion of interferon a (IFNa) and exerted a significant antitumor effect in CEA.Tg mice challenged with a syngenic tumor cell line expressing CEA and an additive effect with a CEA vaccine. Additionally, combination of SM360320 with plasmid encoding the extracellular and transmembrane domain of ratHER2/neu affected the spontaneous tumor progression in BALB-neuT mice treated in an advanced disease setting. The antitumor effect in mice treated with DNA-EP and SM360320 was associated with an anti-CEA and anti-p185 neu antibody isotype switch from IgG1 to IgG2a. These data demonstrate that SM360320 exerts significant antitumor effects and can act in association with DNA-EP for CEA-positive colon cancer and HER2-positive mammary carcinoma. These observations therefore emphasize the potential of SM360320 as immunological adjuvant for therapeutic DNA vaccines.
Introduction
DNA vaccines are well-defined molecular reagents that are easy to construct and elicit long-lasting cellular and antibody immune responses to a variety of antigens. 1 In the area of tumor prevention, DNA vaccines have become the preferred method of antigen delivery in preclinical studies as they are non-toxic. 2 Antitumor DNA vaccines have been shown to elicit cellular and antibody immune responses with significant effect on tumor growth and development in preclinical models. 3 In the clinical setting, however, the ability of DNA vaccines to elicit both immune and antitumoral responses has been limited.
Enhancement of DNA vaccine potency is one of the key objectives of DNA vaccine research today and this objective is currently being pursued through a variety of different, yet complementary, strategies. 4 Several different vaccination approaches have been tested and, among these, in vivo electroporation of plasmid DNA (DNA-EP) has been shown as a safe method resulting in greater DNA uptake leading to enhanced protein expression in the treated muscle. 5 Enhancement of protein expression has been associated with increase in immune responses to the target antigen in a variety of species. [6] [7] [8] [9] [10] Similarly, a number of adjuvants such as cytokines, co-stimulatory molecules and chemotherapeutic agents are being tested both in the laboratory and the clinic. [11] [12] [13] [14] Among them are toll-like receptor (TLR) agonists, which are being utilized to harness the ability of the innate immune system to respond to microbial and viral infections and direct them to develop a stable, long-lasting immune response against tumor antigens.
15, 16 The ensuing adaptive immune response depends on the magnitude and intensity of the preceding innate immune response. 17 Each member of the TLR family has specific ligands/agonists ranging from lipopeptides for TLR1, LPS for TLR4, to imidazoquinolines for TLR7 and 8. [18] [19] [20] Activation of TLRs leads to a cascade of cytokines and chemokines, which eventually lead to productive T-and B-cell responses. 21 Among TLR agonists, substituted 8-hydroxyadenosine derivatives showed interesting profiles and were proposed as a potential drug to treat HCV infection in view of their ability to bind TLR7 in an in vitro assay and to elicit significant interferona (IFNa) production on oral administration in mice. 22 For cancer vaccines, the most widely used preclinical models for immunologic and antitumoral studies are transgenic rodents expressing human tumor-associated antigens because they show central and/or peripheral tolerance to them. 23, 24 Among them, CEA and HER2/neu have robust mice models. CEA is a membrane 180 kDa glycoprotein overexpressed in 90% of colorectal, 70% of gastric, pancreatic and non-small cell lung cancers and 50% of breast cancers. 25 Similarly, the HER2/neu oncoprotein is a tyrosine kinase receptor overexpressed in several human tumors and associated with poor prognosis. 26, 27 CEA transgenic mice (CEA.Tg) are a useful model as tissue distribution of hCEA is similar to that in humans. 23 We have shown earlier that CEA genetic cancer vaccines show significant antitumoral activity in CEA.Tg mice, mainly as prophylactic vaccines. 28, 29 However, significant effects can also be achieved in a therapeutic setting by adding immune modifiers such as the anti-CD25 antibody. 29, 30 Female BALB/c mice transgenic for the mutated rat HER2 gene (BALB-neuT) expressed specifically in the mammary glands are an optimal model for HER2-mediated breast cancer.
2,31 DNA vaccination has been shown to be effective as a prophylactic method in BALB-neuT mice. Numerous studies have demonstrated the prevention of spontaneous development of mammary tumors occurring in these mice at an early age. 2 The combination of cytokines or immuno-regulatory molecules, together with HER2/neu-encoding DNA plasmid, has been shown to increase the effectiveness of the HER2/ neu vaccines. [32] [33] [34] These studies provided the groundwork for the testing of TLR agonists as adjuvants.
In this study, we evaluated DNA-EP vaccination in combination with a TLR7 agonist in two well-characterized mouse models for development of CEA and HER2/ neu cancer vaccines. We demonstrate that the substituted 8-hydroxyadenosine derivative SM360320 has a significant impact on tumor protection in CEA.Tg and BALBneuT mice when combined with DNA-EP and characterize the immunologic parameters associated with this effect. Most interestingly, this combination treatment delays tumor progression also when initiated in an advanced and more aggressive disease setting. Hence, we propose SM360320 as an immunological adjuvant that effectively synergizes with DNA vaccination.
Materials and methods
Mice and DNA immunizations C57Bl/6 mice (H-2 b ) transgenic for the human CEA were obtained from J Primus (Vanderbilt University, Nashville, TN, USA). 23 They were immunized with 50 mg of plasmid DNA, pV1J/CEA-LTB, encoding codon optimized hCEA fused to the B subunit of Escherichia coli heat-labile enterotoxin 28 injected in the quadriceps muscle followed by electroporation. Tumor challenge was performed by subcutaneous injection of 5 Â 10 5 CEA expressing MC38 colon adenocarcinoma cells. Female BALB/c mice (H-2 d ) transgenic for the transforming neuT oncogene (neuT þ / neuT) under the transcriptional control of the MMTV promoter and transgene negative (neuT À /neuT À ) were bred under specific pathogen-free conditions by Charles River (Calco, Italy). Mice were screened for the presence of the transgene by duplex PCR as described. 35 The ECD.TM region (comprising the first 679 amino-acid residues) of a codon optimized version of the rat neu gene was cloned under the control of the human CMV promoter in the plasmid, pV1J/rHER2ECD.TM. Plasmid DNA was used to vaccinate neuT mice at various time points (weeks of age) by DNA-EP as described earlier. 36 Pre-immune sera were collected a week prior to vaccination 2 weeks after administering the second DNA injection. In some cases, sera were collected several weeks after vaccination. Control mice were immunized with saline solution.
Treatment with SM360320 9-Benzyl-8-hydroxy-2-2-methoxyethoxy) adenine was synthesized according to the procedure described in literature. 22 Mice were dosed daily at 3 mg kg
À1
. Appropriate amounts of the compound were dissolved in 0.5% methylcellulose and 100 ml was administered to each mouse per os by gavage.
Pharmacokinetic studies BALB/c mice were dosed once with 3 or 10 mg kg À1 of SM360320. At different times (starting from 15 min to 18 h after administration), 250 ml of blood was collected (three mice per time point) using heparinized Pasteur pipettes. Blood was immediately centrifuged at 900 g for 10 min at 4 1C. Plasma samples (50 ml) were extracted with 200 ml acetonitrile and the supernatant was injected onto LC/MS/MS system for analysis. Detection was carried out using a triple quadrupole tandem mass spectrometer (API 3000; Applied Biosystems, Foster City, CA) equipped with a turbo ion spray. An internal control was used as a standard. Data were analyzed with the Watson LIMS system (Thermo Fisher Scientific Inc., Waltham, MA, USA). Kinetics of IFNa production was measured by ELISA using a kit and following the manufacturer's instructions (Cell Sciences Inc., Canton, MA).
TLR-binding assay TLR activity was determined by using HEK293/TLR clones (Invivogen, San Diego, CA, USA) by means of a luciferase assay that was linked to NF-kB activation according to the manufacturer's instructions (http:// www.invivogen.com/PDF/293XL-hTLR7_TDS.pdf).
Evaluation of spontaneous tumor growth in BALB-neuT mice BALB-neuT females were inspected weekly and tumor masses were measured with calipers in two perpendicular diameters. Progressively growing masses 43 mm in mean diameter were regarded as tumors. Growth was monitored until all mammary glands displayed a palpable tumor or its diameter exceeded 10 mm, at which time mice were killed for ethical reasons. Except where otherwise specified, surviving BALB-neuT mice were killed at week 33.
Intracellular cytokine staining
IFNg production was measured as described earlier. 35, 37, 38 Briefly, 1-2 million mouse peripheral blood mononuclear cells were isolated from blood by standard Oral TLR7 agonist in transgenic mouse tumor models S Dharmapuri et al protocols in RPMI medium. Cells were incubated overnight with appropriate amounts (5-6 mg ml
À1
) of a known immunodominant CD8 þ epitope of ratneu (TYVPA-NASL). Cells were washed, stained with surface antibodies, fixed, surface stained with APC-anti-mouse CD3e, PE-anti-mouse CD4 and PerCP-anti-mouse CD8a. Lymphocytes were then permeabilized with BrefeldinA (1 mg ml
; Pharmingen, San Diego, CA), and incubated with fluorescein isothiocyanate (FITC)-conjugated IFNg antibody (all antibodies from Pharmingen). Cells were analyzed on a FACSCalibur flow cytometer, using CellQuest software (BD Biosciences Immunocytometry Systems; BD Biosciences, San Jose, CA). At least 15 000 gated events were acquired to analyze the immune response.
Titration of anti-neu and anti-CEA antibodies Antibodies against neu were measured by ELISA. Here, 96-well plates were coated with anti-hFc antibody (Pierce, Rockford, IL) overnight at 4 1C. Supernatant from a HEK293 expressing a soluble fusion protein, ratneu ECDhFc, was layered over the antibody followed by sera from DNA-EP immunized mice. Alkaline phosphatase-linked antibodies against total IgG, IgG1 or IgG2a (Pharmingen) were used as secondary antibodies. Antibodies against CEA were measured by coating 96-well plates with purified CEA protein, hybridizing with sera and detecting with alkaline phosphatase-linked antibodies. 29 Plates were read on an ELISA reader at an optical density of 405-620. Serum dilution was plotted vs optical density values and fitted with a Michaelis-Menten curve using Kaleidagraph (v3.5; Synergy Software, Reading, PA).
Statistical analysis
Treatment groups were compared with respect to tumorfree survival (time to first tumor), time to advanced disease (time to tumors in 50% of the mammary glands) and tumor multiplicity at 26 weeks by log-rank test. Tumor volumes were compared at each time point by Student's t-test. P-values less than 0.05 were considered significant.
Results

TLR agonist activity of SM360320
To verify whether SM360320 was indeed an agonist capable of activating the TLR7 downstream pathway, a luciferase assay was performed using HEK293-derived cell lines. These cells have been engineered to report NFkB activation following TLR7-or TLR3-specific triggering. Imiquimod, a known TLR7 agonist 39 and poly I:C, a known TLR3 agonist and IFNa inducer 40 were used as controls in this experiment. Figure 1 shows that SM360320 is a TLR7 agonist and its activity is comparable to that of imiquimod. On the other hand, it shows little affinity for TLR3 as minimal luciferase activity was induced in the cells expressing TLR3. Biological activity of SM360320 was also assessed on mouse splenocytes by measuring cytokine secretion, as reported earlier. 16 Splenocytes from mice were stimulated in vitro with SM360320. An increase in IFNa and IL2 production was observed with respect to untreated lymphocytes (data not shown).
Kinetic studies
To measure the pharmacokinetics and availability of SM360320 in vivo following per os delivery, two dosages (3 and 10 mg kg À1 ) were tested in BALB/c mice. Figure 2 shows that the compound is metabolized at similar rates at both doses fairly quickly within 4 h. An average of 100 ng ml À1 was detected 30 min after administration but this declined fivefold within 4 h (20 ng ml À1 ). Basal levels were detected 7 h after administration and low persistence (o10 ng ml À1 ) was detected after that time point (Figure 2a) . The lower dose, 3 mg kg
À1
, was selected for all further experiments.
To assess the biologic effects induced by SM360320, C57Bl/6 mice were administered per os the TLR7 agonist at the dose of 3 mg kg À1 and bled at 2, 6 and 24 h after treatment. IFNa production peaked at 2 h after administration and decreased rapidly thereafter (Figure 2b ). Similar data were obtained with CEA.Tg and BALB/c strains (not shown). This secretion rate is compatible with the pharmacokinetic data as the compound is metabolized rapidly within 4 h and IFNa half-life is of few hours. 41 Low levels are detected by ELISA at 6 h after administration. These data indicate that daily injections of SM360320 produced substantial amounts of IFNa. As recent evidence suggests, IFNa can enhance and sustain CD8 þ T cells induced by tumor antigens with tumoricidal effects. 42 Antitumor effect of SM360320 in CEA.Tg mice The antitumor activity of SM360320 as monotherapy was tested on CEA.Tg mice in a therapeutic setting by testing three dosing protocols. Mice were challenged Figure 1 Binding of SM360320 to toll-like receptor7 (TLR7) as demonstrated by activation of the NF-kB promoter. Data are expressed as relative luciferase activity by dividing firefly luciferase activity with that of Renilla luciferase. Data show the extent of fold activation as measured by the activity of luciferase. A standard kit was used and the manufacturer's instructions were followed (as indicated in Materials and methods).
Oral TLR7 agonist in transgenic mouse tumor models S Dharmapuri et al subcutaneously (s.c.) with the colon adenocarcinoma cell line MC38-CEA 43 and then treated with SM360320 when tumors were well established (25-50 mm 3 ). Mice were dosed per os at 3 mg kg À1 daily for 7 days starting from day 7 after tumor challenge and supplemented with three further injections of SM360320 at days 21, 28 and 35 (regimen A). A second cohort of mice received the compound only for the initial 7 days (regimen B) and a third group was treated only at days 21, 28 and 35 (regimen C). Untreated mice were also included in the study. Figure 3 shows that regimen A was most effective in inhibiting tumor progression as 33% of the treated mice remained tumor-free up to 50 days after tumor challenge (P ¼ 0.002). These data demonstrate that SM360320 showed a distinct antitumor effect in this model, and a near chronic administration was more effective than a lower number of injections.
Effects of administration of SM360320 in combination with DNA-EP in CEA.Tg mice To investigate whether the antitumor effect of SM360320 could synergize with DNA-EP, CEA.Tg mice were challenged with the MC38-CEA cells and then dosed with SM360320 using the best regimen that was identified in the previous experiment (regimen A). The impact of SM360320 on tumor growth was compared with that of vaccine alone or with the combination of DNA-EP and SM360320. For this study, vaccination was carried out with plasmid pV1J/CEA-LTB injected four times at weekly intervals 29 and the impact of the treatment was determined by monitoring tumor-free mice and tumor volume. As shown in Figure 4a , treatment with either DNA-EP or SM360320 exerted a limited effect as these two groups showed 22 and 33% of mice, respectively, remaining tumor free at day 50 post challenge. In contrast, treatment with SM360320/DNA-EP resulted in 55% (five out of nine) of tumor-free mice. Nonetheless, inhibition of tumor growth was noted on treatment with either SM360320/DNA-EP or SM360320 alone by measuring tumor volumes of the treated mice. In fact, in both groups, tumor size was significantly smaller than control or DNA-EP-treated mice (Figure 4b ).
To verify whether SM360320 had an impact on the immune response elicited by pV1J/CEA-LTB, T cell and antibody responses were measured 2 weeks after the last DNA-EP (50 days post-tumor challenge). CEA-specific T-cell responses were measured by intracellular staining for IFNg, whereas antigen-specific antibody titer was determined by ELISA. No difference between groups vaccinated with or without the adjuvant could be observed for cell-mediated response (data not shown) as well as for total antibodies against CEA (Figure 5a) . However, the administration of SM360320/DNA-EP resulted in a dramatic increase in the IgG2a to IgG1 ratio as compared with DNA-EP (Figure 5b) . No antibody response to CEA was detected in SM360320-treated mice (data not shown).
Therefore, this demonstrated that there was no clear therapeutic synergy between the TLR7 agonist and CEA vaccine in this model system (CEA.Tg). However, coadministration of SM360320 and DNA-EP resulted in the enhancement of the Th1 response to the tumor antigen.
Antitumor effect of an SM360320 with DNA-EP in BALB-neuT mice To determine whether the antitumor effects exerted by SM360320 could be observed in other model systems for tumor development, BALB-neuT mice were immunized with DNA-EP at weeks 10 and 12. Mice were vaccinated with plasmid pV1J/HER2.ECDTM encoding the extracellular and transmembrane domain of ratHER2. Daily SM360320 dosing was commenced at 8 weeks and was continued concomitantly for the entire period of the experiment. Treatment with either DNA-EP or SM360320 impacted tumor progression in a similar manner as shown by the lower mean tumor number than saline group (Figure 6a ) and a 15% tumor-free survival at week 33 ( Figure 6b) . By contrast, an enhanced antitumor effect was exerted on co-administration of both agents. Treatment with SM360320/DNA-EP significantly impacted tumor growth (Figure 6a ; P ¼ 0.0003) and To assess whether the synergy of SM360320 and DNA-EP can also take place in older BALB-neuT mice, immunization was carried out at weeks 13 and 15. At this age, well-established mammary carcinoma in situ are present 31 and can be detected by ultrasound imaging.
44
SM360320 dosing was commenced a week before immunization. The effect on tumor development was monitored over time. Figure 6c shows that treatment with DNA-EP or SM360320 had a limited impact on the tumor progression as mean tumor number for these groups reached 7 and 6, respectively, by week 30. By contrast, a significant synergy was observed in the SM360320/DNA-EP group where mean tumor number remained at two per mouse at week 30. The kinetic of tumor growth was essentially unaffected by either agent as maximal tumor-free survival in these two groups was 20%, whereas 80% of the mice treated with SM360320/ DNA-EP remained tumor free throughout the course of the study (Figure 6d ). To verify whether the SM360320/DNA-EP could exert an antitumor effect in an advanced disease setting, BALBneuT mice were immunized at weeks 16 and 17. At this age, some of the mice already had palpable tumors. As evident from Figure 7 , neither DNA-EP nor SM360320/ DNA-EP was successful in slowing down tumor development. However, a significant difference was observed in the mean tumor number between the two groups. The SM360320/DNA-EP-treated mice had a significantly lower number of tumors per mouse when compared with vaccine-treated mice. Mice could not be maintained for tumor monitoring beyond week 25 because of the high multiplicity of tumors and had to be killed for ethical reasons. These results demonstrate that SM360320 synergizes very effectively with DNA-EP.
Effect of SM360320 treatment on cellular and humoral immunity in BALB-neuT mice To monitor the immunologic effect of SM360320 in combination with DNA-EP, we measured the cellmediated immune response by intracellular staining, as done earlier for CEA.Tg mice. No significant differences were observed between the groups, indicating that SM360320 dosing did not influence the direct immune response elicited by DNA-EP (data not shown).
Anti-neu antibodies were measured by ELISA. Figure 8 shows the titer of anti-neu antibodies and the IgG isotype of the antibody response against ratHER2/neu. At 2 weeks after the second DNA-EP vaccination, antibodies against ratHER2 were found to be slightly higher in mice treated with SM360320/DNA-EP than with DNA-EP alone. In agreement with the earlier observations in CEA.Tg mice, a highly significant difference was observed between the two groups when IgG isotyping was performed. Mice treated with SM360320/DNA-EP Figure 3 Antitumor effect of SM360320 in CEA.Tg mice. Three regimens of SM360320 dosing were tested in CEA.Tg mice. The best antitumoral effect was achieved with regimen A (log-rank test vs untreated: P ¼ 0.002) followed by regimen B (P ¼ 0.04). No significant difference with untreated group was obtained with regimen C (P ¼ 0.485). The experiment was performed with 10-12 mice per group and repeated once with similar results.
Oral TLR7 agonist in transgenic mouse tumor models S Dharmapuri et al showed antibodies mainly of the IgG2a subclass with a minor IgG1 component. The ratio of IgG2a to IgG1 was as high as 9:1 as opposed to 1:1 for the group treated with DNA-EP alone. This dominance of the IgG2a subclass was observed in mice at week 17 as well as at week 29, suggesting that daily dosing with SM360320 was maintaining this characteristic feature of a Th1-type immune response.
Discussion
In this study, we have evaluated the antitumor properties of SM360320 in two mouse tumor models. The data obtained clearly demonstrate that SM360320 is capable of exerting an antitumor effect when utilized as monotherapy, but can also act in synergy with DNA vaccines leading to an enhanced Th1 antibody response and increased therapeutic effect. SM360320 is a TLR7 agonist as shown by its ability to activate the TLR7 pathway (Figure 1 ) leading to induction of IFNa and other Th1 cytokines (Figure 2) . These results confirm the ability of the compound to activate the TLR7 pathway and provide, at least in part, an explanation for its antitumor effects observed on repeated administration of the compound in CEA.Tg mice challenged with a syngeneic tumor cell line. Indeed, induction of IFNa expression has been demonstrated to Oral TLR7 agonist in transgenic mouse tumor models S Dharmapuri et al exert an antitumor effect in cancer. 45 Its antitumor effect may be due to a direct inhibition of cell growth and to stimulation of the innate and adaptive immune responses that ultimately delay or eradicate pre-existing tumors. The therapeutic effects noted following SM360320 injection are in agreement with published data demonstrating that Figure 6 Inhibition of mammary carcinogenesis in BALB-neuT mice. Animals were dosed daily with SM360320 per os from 8 weeks of age. This was combined with vaccinations of pV1J/rHER2ECD.TM and EP at weeks 10 and 12. SM360320 alone and saline-treated animals were used as controls. It is interesting to note that maximal inhibition of tumor growth is observed with a dosing regimen requiring multiple injections of the TLR7 agonist (Figure 3 ). Although we cannot exclude that the antitumor effect may be ascribed to the expression of multiple cytokines and it is not solely associated with the production of IFNa, it is likely that repeated injections of SM360320 are required to achieve a sustained level of cytokine production throughout the course of tumor growth, particularly in view of the relatively short half-life of IFNa observed in the injected mice. SM360320 can act in synergy with DNA vaccines targeting CEA or HER2 as demonstrated by the increased antitumor effects observed on co-administration of DNA-EP and TLR7 agonist (Figures 4, 6 and 7) . The antitumor effect of SM360320 is, however, more obvious in the BALB-neuT model where significant levels of tumor-free survival are observed on treatment with SM360320/DNA-EP as compared with either agent alone (Figures 6 and 7) . In addition to the antitumor effect noted in the prophylactic setting where mice are treated with SM360320 from week 8 onward and are vaccinated at weeks 10 and 12, a significant inhibition of tumor progression is also detected on treatment with SM360320 initiated at week 12 and vaccination at weeks 13 and 15. At this age, there are imaging and histological evidences of neoplasia in mouse mammary glands 33 and the radical improvement of tumor-free survival observed with the combined treatment demonstrates the potency of SM360320/DNA-EP ( Figure 6 ). Moreover, there was an appreciable effect on mean tumor number even when tumor-bearing mice were vaccinated and treated with SM360320 after week 15 ( Figure 7 ). These results demonstrate for the first time the efficacy of a vaccination protocol when combined with a TLR7 agonist in BALBneuT mice with physiologically complex tumors. These results are in agreement with published data demonstrating the utility of TLR agonists as adjuvant to DNA vaccine in a relatively less malignant HER2/neu model (FVB/neuN) albeit in a prophylactic setting. 16 The data obtained in the CEA.Tg and BALB-neuT models suggest that the positive synergy of SM360320 treatment with DNA-EP is a result of immuno-modulation. Remarkably, in both mouse models, the use of SM360320 had a significant impact on the IgG2a antibody class (Figures 5 and 8) . The administration of the compound in BALB-neuT initiated as well as maintained the dominance of the IgG2a isotype. In animals immunized with DNA-EP only, IgG1 and IgG2a titers were relatively the same. The shift in antibody isotype is very significant as it suggests that an effector arm of the B-cell response is being influenced by SM360320. A similar IgG2a bias has been observed Figure 7 Effect of combinatorial treatment of in vivo electroporation of plasmid DNA (DNA-EP) and SM360320 in mice with palpable tumors. BALB-neuT mice were vaccinated with DNA-EP (pV1J/ rHER2ECD.TM) at weeks 16 and 17 alone or in combination with daily dosing of SM360320 per os from 14 weeks of age after DNA-EP. Mean tumor number incidence and standard deviation for tumor incidence per mouse are shown. The difference between the groups is statistically significant (Po0.05). In some of these experiments, mice had to killed by week 25 for ethical reasons. Oral TLR7 agonist in transgenic mouse tumor models S Dharmapuri et al earlier for TLR7 agonists in the FVB/neuN model 16 as well as TLR9 agonists, CpG oligonucleotides, in BALB/c. 18 The reason why the combination of DNA-EP and SM360320 showed synergy in BALB-neuT, but not in CEA.Tg, may reside, at least in part, in the difference between the two tumor models. CEA.Tg mice do not develop spontaneous polyps or gastrointestinal tumors and are challenged subcutaneously with a fast-growing and aggressive colon carcinoma cell line before treatment. Here, the innate immunity could immediately play a dominant antitumoral role, whereas the adaptive response requires more time to reach sufficient antigen-specific activation. As a matter of fact, therapeutic protocols cannot be extended to more than 35-50 days postchallenge. On the other hand, the great advantage of BALB-neuT mice is that they provide a spontaneous and progressive, albeit considered aggressive, tumor model that can be evaluated for several weeks and allows mounting an effective immune response when tumor burden is relatively low. In this context, in our lab we have observed that genetic vaccines targeting CEA are therapeutically efficacious in CEA.Tg with colon-induced carcinogenesis and APC1638N/CEA double transgenics that resemble familial adenomatous polyposis, both models having a tumor progression similar to that of humans. 47 In addition to the differences in biological features between the two tumor models, the sensitivity of HER2-driven tumors to an antibody response may have ultimately determined the greater efficacy of SM360320/ DNA-EP observed in these mice. The role of antibodies for long-lasting protection of Balb-neuT mice has been well documented. 48, 49 In addition, the role of IgG2a as the critical effector isotype has also been described. 50 By contrast, the use of anti-CEA antibodies as therapeutic agents for the treatment of CEA-driven tumors has not provided clear evidence of therapeutic efficacy in preclinical models as well as in clinical trials. 51 It is interesting to note that, although the SM360320/ DNA-EP had an impact on the antibody response to CEA and HER2, SM360320 did not significantly augment the antigen-specific CD8 þ T cells measured by IFNg secretion. Induction of cytokines by TLR agonists has been shown to play a key role in potentiation of the immune response to target antigens. 32, 48 This observation is in contrast to the reported enhancement of T-cell response to antigens injected as proteins or peptides when co-administered with TLR agonists. 16 Although the lack of detection of any changes in the amplitude of HER2-or CEA-specific T-cell response may simply be due to technical reasons and to the need to evaluate additional immunological parameters, it may also suggest that either the nature of the antigen may in some way influence the adjuvant effect exerted by the TLR agonist or that the delivery and formulation of the vaccine and the TLR agonist can determine the immunological outcome of the combined treatment. Nonetheless, CpG monotherapy has been recently shown to be effective in the BALB-neuT model. 52 Direct injections of CpG oligonucleotides in mammary glands impaired tumor growth and this was correlated with local infiltrates of CD11b þ cells with macrophage morphology. In addition, plasma cells, B220 þ B cells, and CD4 þ and CD8 þ T cells were shown to be recruited to the CpG-treated glands.
One of the drawbacks of cancer vaccines developed in mice models in general has been their inability to elicit immune and antitumor responses in humans. One of the most likely causes for this is that in cancer patients tumors are more sophisticated than their murine counterparts and refractory to immunotherapy and chemotherapy. As patients already have detectable tumors at the time of immunization, a therapeutic regimen incorporating multiple vaccinations and long-term adjuvant treatment is a possible remedy. Increasingly, immune response modifiers are being screened and recruited for use in conjunction with DNA vaccines. In this study, we suggest that TLR7 agonists such as SM360320 are a class of immunomodulators that could in the near future provide a substantial boost to obtaining positive results in clinical trials.
